EUVIMEDEUVIMED entdecken
Crossref

Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Debika Bhattacharya iD, Andrew Aronsohn, Jennifer Price, Vincent Lo Re, AASLD-IDSA HCV Guidance Panel

Clinical Infectious Diseases · 25.05.2023

DOI: 10.1093/cid/ciad319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 25.05.2023. Verfasst von Debika Bhattacharya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA. Die Arbeit wurde bisher 280-mal zitiert (Crossref) und nennt 169 Literaturangaben. Gefördert von: AASLD, IDSA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Infectious Diseases Society of America and the American Association for the Study of Liver Diseases have collaboratively developed evidence-based guidance regarding the diagnosis, management, and treatment of hepatitis C virus (HCV) infection since 2013. A panel of clinicians and investigators with extensive infectious diseases or hepatology expertise specific to HCV infection periodically reviews evidence from the field and update existing recommendations or introduce new recommendations as evidence warrants. This update focuses on changes to the guidance since the previous 2020 published update, including ongoing emphasis on recommended universal screening; management recommendations for incomplete treatment adherence; expanded eligibility for simplified chronic HCV infection treatment in adults with minimal monitoring; updated treatment and retreatment recommendations for children as young as 3 years; management and treatment recommendations in the transplantation setting; and screening, treatment, and management recommendations for unique and key populations.

Schlagwörter

Stichwörter der Autor:innen

HCV guidanceHCV preventionHCV screeningHCV treatmentdirect-acting antivirals

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA.
  • Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago.
  • Division of Medicine, Department of Gastroenterology and Hepatology, University of California, San Francisco.
  • Department of Medicine, Division of Infectious Diseases and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine.

ORCID-Profile: Debika Bhattacharya

Förderung

  • AASLD
  • IDSA

Zitieren

APA

Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., & AASLD-IDSA HCV Guidance Panel (2023). Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad319

Vancouver

Bhattacharya D, Aronsohn A, Price J, Lo Re V, AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad319

BibTeX
@article{Bhattacharya2023,
  author = {Bhattacharya, Debika and Aronsohn, Andrew and Price, Jennifer and Lo Re, Vincent and AASLD-IDSA HCV Guidance Panel, AASLD-IDSA HCV Guidance Panel},
  title = {Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad319}
}
Kostenlos starten →